BioCentury
ARTICLE | Financial News

Genentech meets Street consensus, Idec to eclipse

July 17, 2000 7:00 AM UTC

DNA reported second quarter EPS of $0.29, hitting the consensus Street estimate. The EPS number excludes $98.1 million in recurring charges related to the redemption of DNA special common stock by Roche (SWX:ROCZ) in 1999. Second quarter sales of Rituxan rituximab, an anti- CD20 antibody to treat non-Hodgkin's lymphoma licensed from IDPH, were $102.8 million, a 38 percent increase from $74.4 million in the 1999 quarter. Sales of Herceptin trastuzumab anti- HER2 antibody to treat breast cancer were $66.7 million, beneath the $70 million-$75 million projected range for the quarter and $1.1 million below the first quarter sales of $68.7 million. However, Herceptin sales were up 44 percent compared to the $46.2 million figure in the second quarter of 1999. ...